BIRC5 and colorectal carcinoma: The therapeutic potential of VLPs has also been tested in a CRC murine model using chimeric RHDV‐VLPs containing Topoisomerase IIα (topIIα) and/or survivin epitopes derived from CRC tumor‐associated antigens.